Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.
Infections, cardiopulmonary disease, and second cancers were among the leading causes of nonrelapse deaths in patients receiving CAR T-cell therapy, both in clinical trials and clinical practice.
CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.